<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35581627</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2466</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC pulmonary medicine</Title>
          <ISOAbbreviation>BMC Pulm Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience.</ArticleTitle>
        <Pagination>
          <StartPage>199</StartPage>
          <MedlinePgn>199</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">199</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12890-022-01995-z</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current management of poorly draining complex effusions favours less invasive image-guided placement of smaller tubes and adjunctive intrapleural fibrinolysis therapy (IPFT). In MIST-2 trial, intrapleural 10 mg alteplase (t-PA) with 5 mg of pulmozyme (DNase) twice daily for 72 h were used. We aimed to assess the effectiveness and safety of a modified regimen 16 mg t-PA with 5 mg of DNase administered over 24 h in the management of complex pleural infection.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This was a single centre, prospective study involving patients with poorly drained pleural infection. Primary outcome was the change of pleural opacity on chest radiograph at day 7 compared to baseline. Secondary outcomes include volume of fluid drained, inflammatory markers improvement, surgical referral, length of hospitalisation, and adverse events.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty patients were recruited. Majority, 27 (90%) patients were successfully treated. Improvement of pleural opacity on chest radiograph was observed from 36.9% [Interquartile range (IQR 21.8-54.9%)] to 18.1% (IQR 8.8-32.7%) of hemithorax (P &lt; 0.05). T-PA/DNase increased fluid drainage from median of 45 mls (IQR 0-100) 24 h prior to intrapleural treatment to 1442 mls (IQR 905-2360) after 72 h; (P &lt; 0.05) and reduction of C-reactive protein (P &lt; 0.05). Pain requiring escalation of analgesia affected 20% patients and 9.9% experienced major adverse events. None required surgical intervention.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study suggests that a modified regimen 16 mg t-PA with 5 mg DNase can be safe and effective for patients with poorly drained complex pleural infection. Trial registration The study was registered retrospectively on 07/06/2021 with ClinicalTrials number NCT04915586 ( https://clinicaltrials.gov/ct2/show/NCT04915586 ).</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheong</LastName>
            <ForeName>Xiong Khee</ForeName>
            <Initials>XK</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ban</LastName>
            <ForeName>Andrea Yu-Lin</ForeName>
            <Initials>AY</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ng</LastName>
            <ForeName>Boon Hau</ForeName>
            <Initials>BH</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nik Abeed</LastName>
            <ForeName>Nik Nuratiqah</ForeName>
            <Initials>NN</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nik Ismail</LastName>
            <ForeName>Nik Azuan</ForeName>
            <Initials>NA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nik Fuad</LastName>
            <ForeName>Nik Farhan</ForeName>
            <Initials>NF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Syed Zakaria</LastName>
            <ForeName>Syed Zulkifli</ForeName>
            <Initials>SZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghan</LastName>
            <ForeName>Sheah Lin</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdul Hamid</LastName>
            <ForeName>Mohamed Faisal</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia. faisal.hamid@ppukm.ukm.edu.my.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04915586</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Pulm Med</MedlineTA>
        <NlmUniqueID>100968563</NlmUniqueID>
        <ISSNLinking>1471-2466</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.-</RegistryNumber>
          <NameOfSubstance UI="D003851">Deoxyribonucleases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.21.1</RegistryNumber>
          <NameOfSubstance UI="D003850">Deoxyribonuclease I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.21.1</RegistryNumber>
          <NameOfSubstance UI="C568813">dornase alfa</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.68</RegistryNumber>
          <NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003850" MajorTopicYN="N">Deoxyribonuclease I</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003851" MajorTopicYN="N">Deoxyribonucleases</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016724" MajorTopicYN="Y">Empyema, Pleural</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006784" MajorTopicYN="N">Hospitals, Teaching</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010995" MajorTopicYN="Y">Pleural Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010996" MajorTopicYN="Y">Pleural Effusion</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010959" MajorTopicYN="N">Tissue Plasminogen Activator</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alteplase</Keyword>
        <Keyword MajorTopicYN="N">DNase</Keyword>
        <Keyword MajorTopicYN="N">Empyema</Keyword>
        <Keyword MajorTopicYN="N">Intrapleural fibrinolysis</Keyword>
        <Keyword MajorTopicYN="N">Pleural infection</Keyword>
      </KeywordList>
      <CoiStatement>This study was approved by the Medical Ethics Committee of Universiti Kebangsaan Malaysia Medical Centre, and it is in accordance with the Helsinki Declaration (IV adaptation). Written informed consent was obtained from all participants. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>23</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35581627</ArticleId>
        <ArticleId IdType="pmc">PMC9115979</ArticleId>
        <ArticleId IdType="doi">10.1186/s12890-022-01995-z</ArticleId>
        <ArticleId IdType="pii">10.1186/s12890-022-01995-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hassan M, Patel S, Sadaka AS, Bedawi EO, Corcoran JP, Porcel JM. Recent insights into the management of pleural infection. Int J Gen Med. 2021;14:3415–3429. doi: 10.2147/IJGM.S292705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJGM.S292705</ArticleId>
            <ArticleId IdType="pmc">PMC8286963</ArticleId>
            <ArticleId IdType="pubmed">34290522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies HE, Davies RJO, Davies CWH. Management of pleural infection in adults: British Thoracic Society pleural disease guideline. Thorax. 2010;65(Suppl 2):ii41–ii53. doi: 10.1136/thx.2010.137000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thx.2010.137000</ArticleId>
            <ArticleId IdType="pubmed">20696693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2008;2:Cd002312.</Citation>
        </Reference>
        <Reference>
          <Citation>Maskell NA, Davies CWH, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al.  U.K. controlled trial of intrapleural streptokinase for pleural infection. New England J Med. 2005;352(9):865–74. doi: 10.1056/NEJMoa042473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa042473</ArticleId>
            <ArticleId IdType="pubmed">15745977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouros D, Schiza S, Patsourakis G, Chalkiadakis G, Panagou P, Siafakas N. Intrapleural Streptokinase versus Urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med. 1997;155:291–295. doi: 10.1164/ajrccm.155.1.9001327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/ajrccm.155.1.9001327</ArticleId>
            <ArticleId IdType="pubmed">9001327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamblin SE, Furmanek DL. Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion. Pharmacother J Hum Pharmacol Drug Ther. 2010;30(8):855–62. doi: 10.1592/phco.30.8.855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1592/phco.30.8.855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al.  Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518–526. doi: 10.1056/NEJMoa1012740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1012740</ArticleId>
            <ArticleId IdType="pubmed">21830966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccolo F, Pitman N, Bhatnagar R, Popowicz N, Smith NA, Brockway B, et al.  Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery. Ann Am Thoracic Soc. 2014;11(9):1419–25. doi: 10.1513/AnnalsATS.201407-329OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1513/AnnalsATS.201407-329OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccolo F, Popowicz N, Wong D, Lee YCG. Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. J Thorac Dis. 2015;7(6):999–1008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4466425</ArticleId>
            <ArticleId IdType="pubmed">26150913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majid A, Kheir F, Folch A, Fernandez-Bussy S, Chatterji S, Maskey A, et al.  Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection. A single-center experience. Ann Am Thoracic Soc. 2016;13(9):1512–8. doi: 10.1513/AnnalsATS.201602-127OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1513/AnnalsATS.201602-127OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altmann ES, Crossingham I, Wilson S, Davies HR. Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2019;10:1158.</Citation>
        </Reference>
        <Reference>
          <Citation>Mehta HJ, Biswas A, Penley AM, Cope J, Barnes M, Jantz MA. Management of intrapleural sepsis with once daily use of tissue plasminogen activator and deoxyribonuclease. Respir Int Rev Thoracic Dis. 2016;91(2):101–106.</Citation>
        </Reference>
        <Reference>
          <Citation>Gilbert CR, Gorden JA. Use of intrapleural tissue plasminogen activator and deoxyribonuclease in pleural space infections: an update on alternative regimens. Curr Opin Pulm Med. 2017;23(4):371–375. doi: 10.1097/MCP.0000000000000387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCP.0000000000000387</ArticleId>
            <ArticleId IdType="pubmed">28399008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thommi G, Shehan CJ, McLeay MT. Fibrinolytics in parapneumonic effusions/empyemas. Chest. 2014;146(3):e103–e104. doi: 10.1378/chest.14-0706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.14-0706</ArticleId>
            <ArticleId IdType="pubmed">25180732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Daff S, Maziak DE, Alshehab D, Threader J, Ivanovic J, Deslaurier V, et al.  Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions–analysis of predictors for failure of therapy and bleeding: a cohort study. BMJ Open. 2013;3(2):e001887. doi: 10.1136/bmjopen-2012-001887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2012-001887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semba CP, Weck S, Patapoff T. Alteplase: stability and bioactivity after dilution in normal saline solution. J Vasc Interven Radiol JVIR. 2003;14(1):99–102. doi: 10.1097/01.RVI.0000052297.26939.05.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.RVI.0000052297.26939.05</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popowicz N, Bintcliffe O, De Fonseka D, Blyth KG, Smith NA, Piccolo F, et al.  Dose De-escalation of intrapleural tissue plasminogen activator therapy for pleural infection. The alteplase dose assessment for pleural infection therapy project. Ann Am Thoracic Soc. 2017;14(6):929–36. doi: 10.1513/AnnalsATS.201609-673OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1513/AnnalsATS.201609-673OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdul HMF, Rahaman KM. Retrospective review in a single tertiary centre of patients receiving intrapleural recombinant tissue plasminogen activator (rTPA) with alteplase monotherapy in infective and non infective complex effusion. CHEST. 2019;155(4):83. doi: 10.1016/j.chest.2019.02.357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2019.02.357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faisal M, Fazlin M, Ng BH, Nuratiqah N, Andrea YLB. Low dose intrapleural alteplase and pulmozyme (DNase) in two post-surgical patients with pleural sepsis. Respir Med Case Rep. 2020;30:101111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7270608</ArticleId>
            <ArticleId IdType="pubmed">32518748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faisal M, Farhan R, Cheong XK, Ng BH, Nuratiqah N, Andrea YB. Short-course modified regimen intrapleural alteplase and pulmozyme (DNase) in pleural infection. Respir Med Case Rep. 2020;31:101168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7372138</ArticleId>
            <ArticleId IdType="pubmed">32714827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheong XK, Yu-Lin Ban A, Abdul Hamid MF. Short-course intrapleural alteplase and DNase in complex effusion with bleeding risk. Respirol Case Rep. 2020;8(7):e00648. doi: 10.1002/rcr2.648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/rcr2.648</ArticleId>
            <ArticleId IdType="pmc">PMC7446304</ArticleId>
            <ArticleId IdType="pubmed">32864139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lansley SM, Cheah HM, Vergiliana JFV, Chakera A, Lee YCG. Tissue plasminogen activator potently stimulates pleural effusion via a monocyte chemotactic protein-1–dependent mechanism. Am J Respir Cell Mol Biol. 2015;53(1):105–12. doi: 10.1165/rcmb.2014-0017OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2014-0017OC</ArticleId>
            <ArticleId IdType="pubmed">25474480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanellakis NI, Wrightson JM, Hallifax R, Bedawi EO, Mercer R, Hassan M, et al.  Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients. BMJ Open Respir Res. 2019;6(1):e000440. doi: 10.1136/bmjresp-2019-000440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjresp-2019-000440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman NM, Maskell NA, Davies CW, Hedley EL, Nunn AJ, Gleeson FV, et al.  The relationship between chest tube size and clinical outcome in pleural infection. Chest. 2010;137(3):536–543. doi: 10.1378/chest.09-1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.09-1044</ArticleId>
            <ArticleId IdType="pubmed">19820073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robitaille C, Dupont C, Valenti D, Spicer J, Sirois C, Gonzalez AV, et al.  Retrospective review of intrapleural therapy for pleural infections: “Real life” outcomes and challenges. Can J Respir Crit Care Sleep Med. 2018;2(4):218–223.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
